In the CALGB 10603/RATIFY trial, enrolling 717 FLT3 mutated (ITD and TKD) adult AML patients, the addition of the multikinase inhibitor midostaurin to intensive chemotherapy significantly improved overall survival (OS) and event-free survival (EFS) [23]. Here, FLT3 is linked to acute myeloid leukemia.